Navigation Links
Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
Date:6/27/2011

THE WOODLANDS, Texas, June 27, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that the company presented clinical data from a mechanistic study of LX4211, a dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2), in patients with type 2 diabetes at the 71st Scientific Sessions of the American Diabetes Association (ADA) in San Diego, California.  In addition, the company announced that it has commenced enrollment of patients with type 2 diabetes in its Phase 2b clinical trial of LX4211.

Data from the mechanistic study demonstrated that a single dose of LX4211 significantly increased circulating levels of GLP-1 (active and total) and PYY, important regulators of glycemic and appetite control.  For more information on this program or to download a copy of the poster from the ADA meeting, please visit www.lexpharma.com.

The Phase 2b trial is a randomized, double-blind, placebo controlled study of LX4211 in approximately 285 adult patients (18-75 years) with type 2 diabetes who are not adequately controlled on metformin monotherapy.  Patients will be administered LX4211 in combination with standard metformin therapy over 12 weeks.  Doses will include 75 mg once daily, 200 mg once daily, 200 mg twice daily, 400 mg once daily or placebo.  The primary endpoint of the study is the change from baseline in HbA1c at Week 12.  Secondary endpoints will include percentage of patients achieving HbA1c < 7%, and changes in fasting plasma glucose, 3-hour glucose tolerance test, weight, blood pressure, and triglycerides.  The study will be conducted at approximately 50 sites in the United States.  For additional information on this study, please see www.clinicaltrials.gov (ID NCT01376557).

About LX4211

LX4211 is an orally-delivered small molecule under development as a potential treatment for diabetes.  LX4211 inhibits both sodium-glucose co-transporter type 1 (SGLT1) and sodium-glucose co-transporter type 2 (SGLT2).  SGLT2 is a transporter responsible for most of the glucose reabsorption performed by the kidney.  SGLT1 is a transporter responsible for glucose and galactose absorption in the gastrointestinal tract, and to a lesser extent than SGLT2, glucose reabsorption in the kidney.  For more information on LX4211, please visit www.lexpharma.com.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has four drug candidates in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking" statements, including statements relating to Lexicon's clinical development of LX4211, including characterizations of the results of clinical trials of LX4211, the mechanism of action of LX4211 and the potential therapeutic and commercial potential of LX4211.  This press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct clinical development of LX4211 and preclinical and clinical development of its other potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2010, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
2. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
3. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
4. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
5. Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
6. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
7. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
8. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
9. Lexicon Announces Pricing of Common Stock in Public Offering
10. Lexicon Announces Completion of Public Offering of Common Stock
11. Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ALTO, Calif. , Feb. 8, 2016 Lonza, ... Kodiak Sciences Inc., a biopharmaceutical company designing and developing ... today agreements for the clinical supply of Kodiak,s therapeutic ... multiple sites, including Slough (UK), Visp (CH) and Nansha ... Retinal diseases, such as age-related macular degeneration (AMD), ...
(Date:2/8/2016)... 2016  Avista Pharma Solutions ("Avista Pharma") announced today ... Financial Officer (CFO). Mr. Setzer is a finance and ... various roles within growing technology and life science companies. ... Executive Director of Finance at INC Research, a publicly ... . Previously, Mr. Setzer served as CFO of ...
(Date:2/8/2016)... Feb. 8, 2016 Vestagen Technical Textiles, Inc., ... apparel for healthcare and other demanding applications, today announced ... Officer. He replaces Dale Pfost , PhD, who ... Bold is also joining Vestagen,s Board of Directors. ... of active barrier technologies that combines fluid repellent, antimicrobial ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... Remember the old saying “rub some dirt on ... A~, author of “Calcium Bentonite Clay” the health benefits of integrating clay into a ... the body. , A former motivational speaker, Perry A~ has since dedicated her life ...
(Date:2/8/2016)... ... 08, 2016 , ... FileHold's document management software has been ... cloud hosted environment for FileHold software that is pay per user subscription-based and ... using the FileHold web services API. DocuSyst also advises clients on fully functioning ...
(Date:2/8/2016)... ... February 08, 2016 , ... GrassrootsHealth published ... rate of type 2 diabetes in the GrassrootsHealth cohort with substantially higher vitamin ... a change in public health,” states Carole Baggerly, Director of GrassrootsHealth, “the safety ...
(Date:2/8/2016)... ... February 08, 2016 , ... TopConsumerReviews.com recently awarded their ... removal products. , Moles are derived from a cluster of melanin when exposed to ... wrong places and create a lifetime of embarrassment. Historically, mole removal has ...
(Date:2/8/2016)... , ... February 08, 2016 , ... Guruji Mahendra Kumar ... 10th and 11th, 2016 in honor of his birthday on February 10th. During ... Mahendra Trivedi is known by over 250,000 people from over 40 different countries ...
Breaking Medicine News(10 mins):